Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Pant, Shubham; Fan, Jia; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Philippe; Jieer, Ying; Bridgewater, John A.; Tejani, Mohamedtaki Abdulaziz; Chen, Emerson Yu-Sheng; Wasan, Harpreet Singh; Ducreux, Michel Pierre; Zhao, Ian; Garfin, Phillip M.; Harding, James J.

Publication Date

  • June 1, 2024

webpage

published in

category

volume

  • 42

issue

  • 16